We are seeking investors to help us to next level of our development. Please PM if you are interested.What sets us apart from everyone else in world is that GFS Labs is ISO/IEC 17025 & 65:1996 Accredited, offering an uncompromising standard that is recognized globally.The change in direction to detecting immunotoxic peptides that play a role in the pathogenesis of coeliac disease from the detection of prolamins to the development of a next generation of antibodies.The G12 antibody employed by GFS Laboratories International is the AgraQuant Gluten G12 ELISA and AgraStrip Gluten G12 Lateral Flow Test and this belongs to this next generation. The G12 antibody specifically recognizes the 33-mer of the gliadin protein present in gluten. This toxic fragment was identified by the University of Stanford and published in 2002 in a paper in Science. The G12 antibody was raised against this 33-mer peptide using knowledge gained from this publication, and recognizes the hexapeptide sequence QPQLPY and similar peptides found in barley, rye and oats. In contrast, the R5 antibody was raised against a secalin extract and later the epitope it reacts with was identified as the QQPFP pentapeptide. The distinction between the two antibodies relates to the fact that the G12 antibody specifically targets the toxic fragment that triggers the auto-immune reaction in coeliac patients, rather than a peptide sequence unrelated to clinical outcomes.